6月29日 - ** Viridian Therapeutics（VRDN.O）股价在盘前交易中上涨14.5%，至20.5美元
** 该公司于周五晚间 (link) 宣布，美国食品药品监督管理局（FDA）已批准其用于治疗甲状腺眼病患者的药物
** 该药物Lumvoa的获批基于其对该病活动期和慢性期均可治疗的数据支持
** 维里迪安向路透表示，预计将根据疗程定价，使“Lumvoa”的价格与现有获批的IGF-1R疗法持平
** 预计将于2027年初提交其皮下给药版本的美国上市申请
** RBC资本市场表示：“我们认为‘Lumvoa’的获批是VRDN的一个变革性里程碑，作为该公司首款获FDA批准的药物，它将推动公司从临床阶段迈向商业化阶段”
** 截至上一交易日收盘，该公司股价年内累计下跌42.5%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.